Bosentan and sildenafil: Successful treatment in a sclerodermic patient with refractory ulcers

Reumatismo

Volumn 65, Issue 2, 2013, Pages 71-73

  Catarsi, Eleonora ^a   Doveri, M ^a   Tavoni, A ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Bosentan; Sildenafil; Sistemic sclerosis; Ulcer

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTITHROMBOCYTIC AGENT; BOSENTAN; CALCIUM ANTAGONIST; CORTICOSTEROID DERIVATIVE; ENZYME ANTIBODY; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; TOPOISOMERASE 1 ANTIBODY; UNCLASSIFIED DRUG; ENDOTHELIN RECEPTOR; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; ARTHROPATHY; ARTICLE; CAPILLAROSCOPY; CASE REPORT; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ESOPHAGEAL HYPOTONIA; ESOPHAGUS DISEASE; FEMALE; FINGER ULCER; FOOT ULCER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITALIZATION; HUMAN; HYPERBARIC OXYGEN; HYPOKINESIA; LEG ULCER; LOW DRUG DOSE; RAYNAUD PHENOMENON; REFRACTORY PERIOD; SCLERODERMA; SJOEGREN SYNDROME; SKIN ULCER; TREATMENT OUTCOME; TREATMENT REFUSAL; WOUND DRESSING; DRUG ANTAGONISM; MIDDLE AGED; REMISSION; SYSTEMIC SCLEROSIS;

FEMALE; HUMANS; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, ENDOTHELIN; REMISSION INDUCTION; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; SULFONES;

EID: 84878471479     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2013.79     Document Type: Article

References (12)

1. Sicińska J, Rudnicka L. Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment. Pol Merkur Lekarski. 2008; 25: 196-200. (Article in Polish).
2. Meyer MF, Daigeler A, Lehnhardt M, et al. Therapeutic management of acral manifestations of systemic sclerosis. Med Klin (Munich). 2007; 102: 209-18. (Article in German).
3. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68: 620-8.
4. Kumar U, Gokhle SS, Sreenivas V, et al. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Rheumatol Int. 2013; 33: 1047-52.
5. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010; 69: 1475-8.
6. Cairoli E, Garra V, Martínez M. Sildenafil in the treatment of digital ulcers in patients with systemic sclerosis. Actas Dermosifiliogr. 2009; 100: 830-2.
7. Friedrichson E, Rehberger P, Fuhrmann JT, et al. Fast and efficient healing of sclerodermaassociated acral ulcers with sildenafil. Hautarzt. 2008; 59: 230-2. (Article in German).
8. Colglazier CL, Sutej PG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol. 2005; 32: 2440-2.
9. Della Rossa A, Doveri M, D'Ascanio A, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol. 2011; 40: 323-5.
10. Moinzadeh P, Hunzelmann N, Krieg T. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. J Am Acad Dermatol. 2011; 65: e102-4.
11. Ambach A, Seo W, Bonnekoh B, Gollnick H. Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges. 2009; 7: 888-91.
12. Opitz C, Klein-Weigel PF, Riemekasten G. Systemic sclerosis-a systematic overview: part 2-immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa. 2011; 40: 20-30.